B+
Bull case
25%
Probability
Target price
$5.75
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
CTKB
Cytek BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 showed 6% revenue growth, stronger instrument demand in the U.S. and China, recurring revenue at 35% of trailing revenue, 142 quarterly instrument additions, and a $1 million increase in the 2026 revenue-guidance midpoint [#SEC-8K-2026-08-05].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.1.
What can break
Analyst coverage and peer comparability are limited, and no verified post-earnings target or estimate revisions are available.
Momentum
41
Value
41
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.75 · Bull $5.75 · Bear $3.25Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $5.56
Why
Momentum41 · Δ7d +14.7
Value41 · Δ7d 0.0
Sentiment61 · Δ7d +6.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +6.1.
Contradictions & invalidation
- • Analyst coverage and peer comparability are limited, and no verified post-earnings target or estimate revisions are available.
- • Net loss and adjusted EBITDA deteriorated year over year despite revenue growth [#SEC-8K-2026-08-05].
- • Profitability remains weak: net loss widened year over year, adjusted EBITDA turned negative, operating expenses rose materially, and the reported gross-margin improvement was partly affected by a one-time tariff refund [#SEC-8K-2026-08-05].
Catalyst clock
2026-08-05
Mixed Q2 2026 earnings follow-up
Lead driver: Sentiment · See AI snapshot
Momentum
41
9% active weight
Current posture
7d trendImproving
Δ7d
+14.7
Δ21d
-2.4
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
61
62% active weight
Current posture
7d trendImproving
Δ7d
+6.1
Δ21d
+3.4
Why this grade
Composite grade C. Momentum 40.9 / Value 41.2 / Sentiment 60.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.75
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$616.12M
Beta
1.30
Shares Out
129.98M
P/E (TTM) · Derived
-9.1
P/S (TTM)
3.38
P/FCF (TTM)
53.79
Rev YoY
+5.6%
EPS YoY
+113.4%
Gross Margin
+53.2%
Op Margin
-21.6%
Net Debt
-$228.51M
Current Ratio
4.48
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data